Literature DB >> 22704312

Is there a learning curve for photodynamic diagnosis of bladder cancer with hexaminolevulinate hydrochloride?

Stavros Gravas1, Kostas Efstathiou, Ioannis Zachos, Michael D Melekos, Vassilios Tzortzis.   

Abstract

INTRODUCTION: To assess the learning curve for fluorescence cystoscopy using hexaminolevulinate hydrochloride (HAL) in patients with bladder cancer.
MATERIAL AND METHODS: Fifty patients underwent bladder instillation with HAL. Two senior residents inspected separately the bladder using white light cystoscopy, followed by fluorescence cystoscopy and mapped the lesions. An experienced with photodynamic diagnosis (PDD) urologist also performed both cystoscopies, mapped, resected or cold biopsied suspect lesions under the supervision of another experienced urologist. To evaluate the learning curve, patients were divided into five subgroups, including group 1 (patients 1-10), group 2 (11-20), group 3 (21-30), group 4 (31-40) and group 5 (41-50). The kappa statistics was calculated to assess interobserver agreement between the physicians and the false positive rates of urologists and residents were also compared.
RESULTS: Histologically verified tumors were diagnosed in 103 of 142 lesions identified by PDD. The interobserver agreement between urologists and residents was moderate, moderate, good, excellent, and excellent for group 1, 2, 3, 4, and 5, respectively. Both residents had increased false positive rates compared to urologists in all subgroups of patients but this difference did not reach statistical significance. In addition, false positive rate of residents was declining as the number of procedures was increasing.
CONCLUSIONS: Our data suggest that 20 cases of HAL PDD are required to achieve a good interobserver agreement between inexperienced and experienced operator, and excellent agreement is achieved after 30 cases. The false positive rate of inexperienced operators was comparable to the experts and showed a gradual decrease.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22704312

Source DB:  PubMed          Journal:  Can J Urol        ISSN: 1195-9479            Impact factor:   1.344


  6 in total

Review 1.  The Impact of Blue Light Cystoscopy on the Diagnosis and Treatment of Bladder Cancer.

Authors:  Eugene J Pietzak
Journal:  Curr Urol Rep       Date:  2017-05       Impact factor: 3.092

Review 2.  [Photodynamic diagnostics of the bladder: current study results].

Authors:  A Karl; C Stief; D Zaak
Journal:  Urologe A       Date:  2013-04       Impact factor: 0.639

Review 3.  Hexaminolevulinate blue-light cystoscopy in non-muscle-invasive bladder cancer: review of the clinical evidence and consensus statement on appropriate use in the USA.

Authors:  Siamak Daneshmand; Anne K Schuckman; Bernard H Bochner; Michael S Cookson; Tracy M Downs; Leonard G Gomella; H Barton Grossman; Ashish M Kamat; Badrinath R Konety; Cheryl T Lee; Kamal S Pohar; Raj S Pruthi; Matthew J Resnick; Norm D Smith; J Alfred Witjes; Mark P Schoenberg; Gary D Steinberg
Journal:  Nat Rev Urol       Date:  2014-09-23       Impact factor: 14.432

Review 4.  Hexaminolevulinate blue light cystoscopy: a review of its use in the diagnosis of bladder cancer.

Authors:  Lily P H Yang
Journal:  Mol Diagn Ther       Date:  2014-02       Impact factor: 4.074

Review 5.  Role of Macroscopic Image Enhancement in Diagnosis of Non-Muscle-Invasive Bladder Cancer: An Analytical Review.

Authors:  Prashant Motiram Mulawkar; Gyanendra Sharma; Ashwin Tamhankar; Utsav Shah; Rickaz Raheem
Journal:  Front Surg       Date:  2022-02-21

6.  Deep learning-based classification of blue light cystoscopy imaging during transurethral resection of bladder tumors.

Authors:  Nairveen Ali; Christian Bolenz; Tilman Todenhöfer; Arnulf Stenzel; Peer Deetmar; Martin Kriegmair; Thomas Knoll; Stefan Porubsky; Arndt Hartmann; Jürgen Popp; Maximilian C Kriegmair; Thomas Bocklitz
Journal:  Sci Rep       Date:  2021-06-02       Impact factor: 4.379

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.